Compare Sun Pharma with Pfizer - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs PFIZER - Comparison Results

SUN PHARMA     Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA PFIZER SUN PHARMA/
PFIZER
 
P/E (TTM) x 21.1 36.5 57.6% View Chart
P/BV x 2.5 6.2 40.0% View Chart
Dividend Yield % 0.6 0.6 117.0%  

Financials

 SUN PHARMA   PFIZER
EQUITY SHARE DATA
    SUN PHARMA
Mar-19
PFIZER
Mar-19
SUN PHARMA/
PFIZER
5-Yr Chart
Click to enlarge
High Rs6793,840 17.7%   
Low Rs3752,080 18.0%   
Sales per share (Unadj.) Rs121.1455.0 26.6%  
Earnings per share (Unadj.) Rs13.493.8 14.3%  
Cash flow per share (Unadj.) Rs20.7109.4 18.9%  
Dividends per share (Unadj.) Rs2.7522.50 12.2%  
Dividend yield (eoy) %0.50.8 68.6%  
Book value per share (Unadj.) Rs172.6658.2 26.2%  
Shares outstanding (eoy) m2,399.2645.75 5,244.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.46.5 66.9%   
Avg P/E ratio x39.431.6 124.8%  
P/CF ratio (eoy) x25.527.1 94.2%  
Price / Book Value ratio x3.14.5 67.9%  
Dividend payout %20.624.0 85.7%   
Avg Mkt Cap Rs m1,264,650135,420 933.9%   
No. of employees `00017.52.6 665.2%   
Total wages/salary Rs m59,6713,238 1,842.6%   
Avg. sales/employee Rs Th16,608.17,911.4 209.9%   
Avg. wages/employee Rs Th3,409.61,230.9 277.0%   
Avg. net profit/employee Rs Th1,833.81,630.7 112.5%   
INCOME DATA
Net Sales Rs m290,65920,815 1,396.4%  
Other income Rs m10,2551,674 612.6%   
Total revenues Rs m300,91422,489 1,338.1%   
Gross profit Rs m63,0765,712 1,104.3%  
Depreciation Rs m17,533714 2,455.9%   
Interest Rs m5,55373 7,616.6%   
Profit before tax Rs m50,2466,599 761.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-12,1440-   
Tax Rs m6,0092,309 260.3%   
Profit after tax Rs m32,0934,291 748.0%  
Gross profit margin %21.727.4 79.1%  
Effective tax rate %12.035.0 34.2%   
Net profit margin %11.020.6 53.6%  
BALANCE SHEET DATA
Current assets Rs m310,69227,167 1,143.6%   
Current liabilities Rs m173,3968,917 1,944.6%   
Net working cap to sales %47.287.7 53.9%  
Current ratio x1.83.0 58.8%  
Inventory Days Days9968 146.1%  
Debtors Days Days11230 370.6%  
Net fixed assets Rs m232,4778,862 2,623.3%   
Share capital Rs m2,399458 524.4%   
"Free" reserves Rs m411,69129,656 1,388.2%   
Net worth Rs m414,09130,113 1,375.1%   
Long term debt Rs m15,22625 60,904.4%   
Total assets Rs m646,93839,400 1,642.0%  
Interest coverage x10.091.5 11.0%   
Debt to equity ratio x00 4,429.1%  
Sales to assets ratio x0.40.5 85.0%   
Return on assets %5.811.1 52.5%  
Return on equity %7.814.2 54.4%  
Return on capital %10.222.1 45.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m66,025428 15,415.7%   
Fx outflow Rs m38,610786 4,909.7%   
Net fx Rs m27,415-358 -7,655.7%   
CASH FLOW
From Operations Rs m21,965978 2,245.6%  
From Investments Rs m-6,813351 -1,939.8%  
From Financial Activity Rs m-27,305-1,099 2,485.7%  
Net Cashflow Rs m-8,442231 -3,657.5%  

Share Holding

Indian Promoters % 63.7 0.0 -  
Foreign collaborators % 0.0 63.9 -  
Indian inst/Mut Fund % 5.1 7.5 68.4%  
FIIs % 23.0 4.9 469.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 23.7 35.0%  
Shareholders   133,026 85,207 156.1%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   NATCO PHARMA  PANACEA BIOTECH  WOCKHARDT  ABBOTT INDIA  FRESENIUS KABI ONCO.  

Compare SUN PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 72 Points Lower; Capital Goods and Auto Stocks Witness Selling(Closing)

India share markets witnessed selling pressure during closing hours and ended their day marginally lower.

Related Views on News

PFIZER Announces Quarterly Results (2QFY20); Net Profit Up 61.0% (Quarterly Result Update)

Oct 29, 2019 | Updated on Oct 29, 2019

For the quarter ended September 2019, PFIZER has posted a net profit of Rs 2 bn (up 61.0% YoY). Sales on the other hand came in at Rs 6 bn (up 9.1% YoY). Read on for a complete analysis of PFIZER's quarterly results.

SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, SUN PHARMA has posted a net profit of Rs 15 bn (up 35.3% YoY). Sales on the other hand came in at Rs 84 bn (up 15.9% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

PFIZER Announces Quarterly Results (1QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PFIZER has posted a net profit of Rs 1 bn (up 22.8% YoY). Sales on the other hand came in at Rs 5 bn (up 6.3% YoY). Read on for a complete analysis of PFIZER's quarterly results.

SUN PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 53.4% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, SUN PHARMA has posted a net profit of Rs 7 bn (down 53.4% YoY). Sales on the other hand came in at Rs 72 bn (up 2.7% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Nov 18, 2019 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA - PFIZER COMPARISON

COMPARE SUN PHARMA WITH

MARKET STATS